S. Jezdic

TL;DR: ESMO recommends routine use of NGS on tumour samples in advanced non-squamous NSCLC, prostate cancers, ovarian cancers and cholangiocarcinoma, and develops multigene sequencing as a tool to screen patients eligible for clinical trials and to accelerate drug development.

TL;DR: The first version of the ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prioritise genomic alterations as markers to select patients for targeted therapies.

TL;DR: The national actions and the policy recommendations in this paper set forth the vision of its authors for the future of global cancer control at the national level, where the WHO Cancer Resolution must be implemented if the authors are to reduce the cancer burden, avoid unnecessary suffering and save as many lives as possible.

TL;DR: Analysis of paired sequencing data from 17 152 cancer samples has generated recommendations regarding germline-focussed analyses of tumour-only sequencing data, indications for germline follow-up testing and guidance on patient information-giving and consent.

TL;DR: The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncologists (ASCO) published a new edition of the ESMO/ASCO Global Curriculum (GC) thanks to contribution of 64 ESMO-appointed and 32 ASCO-appointed authors as mentioned in this paper.